Tele-EnhanceFitness for Arthrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Arthrosis+2 More
Tele-EnhanceFitness - Behavioral
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a new pathway can help rural patients with knee osteoarthritis.

Eligible Conditions
  • Arthrosis
  • Knee

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Change from Baseline KOOS Physical Function Subscale score at 12 weeks

Week 12
Active minutes per day
Week 12
Knee injury and Osteoarthritis Outcome Score (KOOS) Physical Function Subscale
Week 12
Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function 8-item Short Form

Trial Safety

Trial Design

1 Treatment Group

Tele-EF
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Tele-EnhanceFitness · No Placebo Group · N/A

Tele-EF
Behavioral
Experimental Group · 1 Intervention: Tele-EnhanceFitness · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline koos physical function subscale score at 12 weeks

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,587 Previous Clinical Trials
1,567,208 Total Patients Enrolled
Kushang V Patel, PhDPrincipal InvestigatorUniversity of Washington

Eligibility Criteria

Age 65+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: November 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.